Mark Boothby, M.D, Ph.D. Curriculum Vitae
CURRICULUM VITAE
June 22, 2012
Name:Mark Robin Boothby
Home address:2104 Twentieth Ave South, Nashville, TN 37212
Work address:AA-4214 MCN, Dept. of Pathology, Microbiology & Immunology,
VanderbiltUniversity Medical School, Nashville, TN 37232-2363
Contact: 615-343-1699
E-mail:
Date of birth:August 16, 1955
Place of birth:Evanston, IL USA
Education:
1976 B.S.University of Wisconsin, Madison, WI
1983 M.D.Washington University School of Medicine,
1983 Ph.D.St. Louis, MO (Molecular Biology)
Postdoctoral training:
Internship and residencies:
1983-1984Intern in Medicine, the University of Colorado
1984-1986Resident in Medicine, the University of Colorado, Denver CO
Fellowships:
1986-1988Research fellow, Harvard Medical School
1986-1989Clinical fellow, Rheumatology, Brigham and Women's Hospital,
Boston MA
1986-1988Postdoctoral fellow, Department of Cancer Biology, Harvard School of Public Health, Boston MA
1989Research Associate, Department of Cancer Biology, Harvard School
of Public Health, Boston MA
Licensure and Certification:
1984Colorado License Registration
1986Diplomate, American Board of Internal Medicine
1989Rheumatology Subspecialty Certification, American
Board of Internal Medicine
1989-1992Massachusetts License Registration
1992-Tennessee License Registration
Academic Appointments:
1988-1989Instructor in Medicine, Harvard Medical School, Boston, MA
1990-1992 Assistant Professor of Immunology, Harvard School of Public
Health, Boston, MA
1990-1992Assistant Professor of Medicine, Harvard Medical School
1992-1997Assistant Professor, Dept of Microbiology and Immunology,
Vanderbilt University, Nashville, TN (primary appointment)
1992-2000Assistant Professor of Medicine, Vanderbilt University (VU).
1998-2005Associate Professor (tenured), Dept. Microbiology and Immunology,
Vanderbilt University, Nashville, TN (primary appointment)
2000-2006Associate Professor, Dept. of Medicine (Rheumatology), VU
2005- presentProfessor (tenured), Dept. Microbiology & Immunology
Vanderbilt University School of Medicine
2006- presentProfessor, Dept. of Medicine (Rheumatology), VUSM
2011-presentProfessor (tenured), Dept. Pathology, Microbiology & Immunology
Hospital Appointments:
1989-1992Associate Rheumatologist, Brigham & Women's Hospital, Boston, MA
1992-2005Part-time Medical Staff, Vanderbilt Univ. Hospital, Nashville, TN
Awards and Honors:
1976Phi Beta Kappa
1976National Science Foundation Graduate Fellowship (declined)
1983Alpha Omega Alpha
1989Hilda Duggan Arthritis Investigator Award, Arthritis Foundation
1989Special Fellow Award, Leukemia Society of America (declined)
1992Special Fellow Award, Leukemia Society of America
1992Baxter Scholar in Immunology, Baxter Foundation
1995Leukemia Society of America Scholar Award
2001Senior Investigator Award, American Asthma Foundation (formerly
Sandler Program for Asthma Research)
2006Faculty of 1000
2011Ernest Goodpasture Award for Research (VUSM)
Professional Societies:
1989American Association for the Advancement of Science
1990American Association of Immunologists
1994Int'l Assoc. for Comparative Res. on Leukemia and Related Diseases
National service - peer review experience (ad hoc):
Grants:Association for International Cancer Research
Human Frontiers Program
Leukemia & Lymphoma Society of America
National Science Foundation
Scleroderma Foundation
VAMC, Merit Review
Journals:Arthritis and Rheumatism
Blood
Cancer Research
EMBO Journal
Genes & Development
Immunity
International Immunology
Journal of Biological Chemistry
Journal of Clinical Investigation
Journal of Experimental Medicine
Journal of Immunology
Molecular and Cellular Biology
Nature Immunology
New England Journal of Medicine
Oncogene
Proceedings of the National Academy of Sciences USA
Respiratory Research
National & international service: meetings, peer review panels, committees, & Boards:
1990Chair, MHC regulation minisymposium, FASEB
1995Co-chair, T cell development minisymposium, FASEB '95
1996-1998Molecular Immunology Study Section, national Arthritis Foundation
1998Chair, IL-4 regulation and signaling Block symposium, FASEB '98
1999NIH CSR, ALY Study Section (ad hoc)
2000NIH / NIAID SEP, Costimulation & Autoimmunity PPG.
2001Co-chair, AAI Symposium on Signaling, Exptl Biology 2001
2001-2004Finance Committee, American Assoc. Immunologists (AAI)
2002NIH CSR, ALY Study Section (ad hoc)
2002NIH CSR, Special Study Section
2002NIH CSR, IMB Study Section (ad hoc)
2004NIH / NIAID Special Emphasis Panel, co-Chair, "Immune System Development and the Origins of Asthma"
2004NIH / CSR Special Emphasis Panel
2004NIH / CSR CMI-A Study Section (ad hoc) (06/04)
2004NIH / CSR CMI-A Study Section (ad hoc) (10/04)
2004-2007Finance Committee, American Assoc. Immunologists (AAI)
2005-2010Board of Directors, Federation of American Societies for
Experimental Biology (FASEB)
2006 Leukemia & Lymphoma Society of America (LLS), national
Career Development Program review committee
2006 NIH / CSR CMI-A Study Section (ad hoc)
2007-present Leukemia & Lymphoma Society of America (LLS), national
Career Development Program review committee
2007-2010 Chair, NIH Issues Subcommittee, FASEB Science Policy Committee
2008-present Charter membership, NIH CSR, CMI-B study section
2010 Program committee, PARP2010 meeting (Zurich, CH)
Invited presentations:
1991University of Florida, Division of Rheumatology, Gainesville, FL
1992Massachusetts General Hospital, Mucosal Immunity seminars,Boston, MA
1992University of Washington, Dept. Immunology, Seattle, WA
1992University of Cinncinnati & Children's Hospital Medical Center
1994Abbott Laboratories, Abbott Park, IL.
1995Experimental Biology '95 meeting, Atlanta, GA
1996Institute for Human Gene Therapy,University of Pennsylvania
1996Virginia Mason Research Center, Seattle, WA
1996U Conn Health Science Center, Div. Rheumatic Diseases,
Farmington, CT
1996San Francisco VA Med Ctr / UCSF, Div. of Rheumatology
1997Division of Inflammatory Diseases, Boehringer-Ingelheim,
Ridgefield, CT
1999Laboratory of Immunology, NIAID, NIH, Bethesda, MD
1999Holland Lab, American Red Cross, Rockville, MD
2000University of Rochester, Rochester, NY
2000University of Vermont Medical School, Burlington, VT
2000Immunology Council, Johns Hopkins School of Medicine,
Baltimore, MD
2001Immunology Colloquium, University of Pennsylvania,
Philadelphia, PA
2001Rheumatology Divisional Conference, Tufts / NEMC, Boston, MA
2001Departmental Seminar series, Medical College of Georgia, Augusta GA
2001Institut de Pharmacologie Moleculaire et Cellulaire, CNRS, Nice, FR
2002 University of Chicago, Immunology Seminar Serie, Chicago IL
2004 Keystone Symposium on NF-kappaB, Snowbird, UT
2004CSH Symposium, Gene Expression & Signaling in the Immune System
2004Tennessee State University (MARC seminar series)
2005University of Maryland - Dover (MARC seminar series)
2005 Center for Biotechnology, University of Turku (Turku, Finland)
2005 Pennsylvania State University, State College, PA
2005 La Jolla Institute of Allergy & Immunology, La Jolla, CA
2006 University of Iowa, Iowa City, IA
2009 City of Hope Seminar Series, Duarte, CA
2010 Duke University, Immunology Seminar Series, Durham NC
2010Keystone Symposium on Lymphocyte Activation and Signaling Breckenridge CO
2010 National Institute on Aging, Baltimore MD
2011 UC-Riverside Medical School, Riverside, CA
2011 Keystone Symposium on Immunologic Memory, Persisting Microbes, &
Chronic Diseases, Banff, Alberta (Canada)
20116th Annual International Conference on Signaling in Leukocytes,
Chania, Crete (Greece)
2012Keystone Symposium on Signaling Regulation in Lymphocytes
2012 St. Jude Medical Center, Dept. of Immunology, Memphis, TN
2012 Genentech, Inc., South San Francisco, CA
2012 National Institute on Aging, Baltimore, MD
pending / booked
2012 Roswell Park Cancer Institute, Buffalo, NY
2013U. Texas MD Anderson Cancer Center, Houston, TX
Trainees:
Predoctoral:
1989-1991Maryann Whitley (D.Sc. thesis advisor; AHA post-doctoral fellow,
Dept. Pathology, Brigham and Women's, Boston;
currently Research Scientist, Genetics Institute, Boston, MA)
1992Alex Dranovsky (M.D., Ph.D, SUNY Stonybrook; currently Assistant Professor, Psychiatry / Neuroscience fellow, Columbia University, NY
(K08 & now R01 awardee as PI)
1996-1999Sarah Stanley (completed Ph.D., UCSF; post-doc @ Broad Inst. & MIT)
1999-2004Linda ('Lynn') Stephenson (nee Dzurek) (VUMC Ph.D. student)
Research Scientist, Sigma-Aldrich, St Louis, MO, after a
post-doctoral fellowship, Dept. of Pathology, Washington University
Medical School, St. Louis MO
2001-2005Radiah Corn (Meharry Medical College Ph.D. student)
Assistant Professor, North Carolina
after a post-doctoral fellowship, NIEHS, Research Triangle, NC
2006-Christopher L. Williams
Post-doctoral:
1989-1990Leslie Casey, Ph.D. (Senior Scientist, Cistron Biotechnology, Pine Brook NJ; currently Senior Director of Research, Elusys, Inc)
1992-1997Ding-Zhi Wang, Ph.D. (currently Professor, Dept. Cancer Biol., MD Anderson Cancer Center, Houston, TX)
1994-1995Bijan Ansari, M.D., Ph.D. (last known position - Asst. Professor of Pathology, Zanjan University, Iran)
1995-2002Mark Aronica, M.D. (Asst. Professor equivalent, Depts. of Medicine, Immunology, Lerner Res. Inst., Cleveland Clinic Foundation)
(K08 & now R01 awardee as PI)
1995-2002Ana L Mora, M.D. (Asst. Professor, Dept. Medicine, Emory University,
now at U. Pittsburgh M.C.) (K01 awardee)
1996-1998Jeehee Youn, Ph.D. (Assoc. Professor, Dept. of Anatomy/Cell Biology,
Hanyang University Medical School., Seoul, Korea)
1997- 2004Shreevrat Goenka, Ph.D. (Assistant Professor, University of Indiana
School of Medicine, Indianapolis, IN)
(R01 awardee as PI)
2001- 2007Eric Adeeku, Ph.D. (staff Microbiologist, US Food & Drug
Administration, Rockville, MD)
2001- 2004Yanhong Zhang, Ph.D. (to Zutter lab, Dept. Pathol., VUSM)
2001- 2006Fuping Zhang, Ph.D. (@ Strober lab, NIAID)
2005-presentSung Hoon Cho, Ph.D.
2005-2008Ross M. Potter, Ph.D. (@ present, 2nd post-doc @ Mayo Scottsdale)
2006-presentKeunwook Lee, Ph.D.
2010-presentMarcia Schilling, Ph.D.
Visiting Faculty & Visiting Scientists:
1996-1998Atsushi Karashima, M.D., Ph.D. (Visiting Scholar; now at Dept. of
Neurosurgery, Oita Medical School, Oita, Japan).
1998Victor Arrunategui-Correa, Ph.D. (visiting scientist)
2004- 2006Do Sim Park, M.D. (Visiting Asst. Professor)
Institutional Committee Work:
1991- 1992Course Coordination Committee, HSPH
1992- 1994Immunology Steering Committee, VUMC
1992- 1995Goodpasture Professorship Search Committee, VUMC
1995- 1996Leukemia / Lymphoma Search Committee, VU Cancer Center
1998LCME Institutional Self-Evaluation; Subcommittee on Resources
for the Educational Mission: Faculty
1999VUMC Discovery Grant review panel
1999 - presentMedical Scientist Training Program Advisory Committee
1999VUMC Discovery Grant Review Committee
2000 - presentCBMS Training Grant Advisory Committee
2001 - 2003 Faculty Advisory Council, VU School of Medicine
1992 - presentQualifying Exam and Thesis Advisory Committees
current roster: C. L. Williams (my lab), J. Williams,
A. Melo, P. Wagner (CDB); K. Amato (pending)
selected past: L. Gordy, Srdjan Dragovic, E. Johnson, M. Vetter, C. Gabriel; K. McCall, N. Shinners, V. Gerbasi, E. Woodward, Z. Liu, A. Stanic, J. Bezbradica; M. Schilling (MPB), J. Stafford (Biochem), L. Yang (Cancer Biol.), J. Ohm (Cancer Biol.)
2005 - 2007Search Committee (Immunology Faculty / Dept. Micro & Immunol.)
2007 - 2008Co-chair, Committee on Measuring Progress (Basic Science update,
Strategic Academic Planning process)
Teaching Experience:
1989 - 1991Lecturer, Immunology 204, Graduate School of Arts and Sciences,
Harvard Medical School
1989 - 1992Presented new lecture series, Topics in Basic Immunology, Departments of Rheumatology/Immunology (BWH), Medicine
(HMS)
1990Bio 91r (supervised reading), Harvard College
1991 -1992Division of Biological Sciences, DBS 210, Molecular Mechanisms of Immune Regulation (developed new course)
1993 - 2001Lecture series, Immunology section, VMS I
1993 - 1994Immunology Lecture sections, VUMC Interdisciplinary Graduate Program
1993- presentFlextime sections, Immunology component, VUMC IGP
1993 - 1994Course director, Graduate Immunology, Vanderbilt University
1994Physical Diagnosis: Rheumatic Diseases, VMS II
1994 - 1995Co-director and Preceptor,
Microbial Topics, VMS I Microbiology & Immunology
1994 - presentCourse faculty, Graduate ("Molecular & Cellular") Immunology
1995 - 2009Preceptor, Microbial Topics, (Coordinator through 2004)
VMS I Microbiology & Immunology
1999 - presentCoordinator and Preceptor: Foundations of Immunology (M&IMM334)
2000 - presentPreceptor and Co-director, MSTP Seminar course
2002 - presentCoordinator, Immunology component of Dept. seminar series
Major Research Interest:Molecular programming of lymphocytes in immune responses:
mechanisms of IL-4 action on lymphocytes;
mechanisms regulating effector function in T lymphocytes --
activation, differentiation, apoptosis, & memory.
Molecular pathogenesis in allergic diseases
Grant Support:
Past:
1989-1992Arthritis Investigator Award
1989-1994N.I.H. R29 GM42550 (F.I.R.S.T. Award)
1992-1995Leukemia Society of America Special Fellow Award
1992-1995Baxter Foundation Scholar’s Award.
1995-1999Interleukin 4 regulation of lymphocyte gene expression.
NIH R01 GM42550
1995-1999Thymocyte activation and apoptosis: genetic analysis. NIH R01AI36997
1995-2000Leukemia Society of America Scholar Award
Thymocyte activation and apoptosis
1997-2000Mouse models to investigate role in T cells of signaling by TNF-R
superfamily members.
Boehringer-Ingelheim Pharmaceuticals (total costs $42,000)
1998-1999Immune Deviation and Diabetes: Effect of a chimeric IL2/4
receptor transgene NIH P60 DK 20593
(Diabetes Research & Training Center Pilot Project)
1999-2000Interleukin 4 regulation of lymphocytes
NIH R 01 GM42550-10S1 (direct costs $45,000)
2001VUMC Discovery Grant: Pilot Project
TCR signaling & NF-B: Molecular regulation & proteomics
annual direct costs $25,000
2001-2002Transcriptional regulation of the type 1 T cell response
NIH R21 AI49460-01 (bridge award; $225,000 direct costs)
1998-2002Allergic airway responses: Immune deviation and memory
NIH R01 HL-61752 (year 04 direct costs ca. $185,000)
2001-2004Memory regulation and allergic airways disease
Sandler Program for Asthma Research (annual total costs $250,000)
2000-2005Interleukin 4 regulation of lymphocytes
NIH R 01 GM42550-14S1
(bridging direct costs ca. $73,000)
2001-2006Program Project: Functional Genomics of Inflammation
NIH P01 HL68744(P.I.- Jack J. Hawiger, M.D., Ph.D.)
Project 3: T-Lymphocyte-Based Functional Genomics of Inflammation
(Van Kaer - Leader; co-investigator, 5% effort)
2006-2008Epitope Discovery via Nanocluster Presentation
NIH 1 R01 GM076479-01
(co-investigator, 3% effort) P.I. - David Cliffel, Ph.D, Dept of Chemistry
2002-2006Transcriptional regulation of the type 1 T cell response
NIH R01 AI49460-04 (modular annual direct costs $225,000)
(no-cost extensions 2/1/06-1/31/09)
2007-2008Role of mTOR complex 2 in T cell leukemia and Notch-induced cancer
Pilot Project, VICC Cancer Center grant (one year award of $35,000)
2004-2008Integration of Stat6, coregulation, and gene expression
NIH R01 GM071735-04(modular annual direct costs, $200,000, reduced
to ~$186,000 with NIH cuts; no-cost extensions 7/1/2008-6/30/2010)
2006-2011Interleukin 4 regulation of lymphocytes
NIH 2 R01 AI068149-19 (No-cost Extension 2011-2012)
CURRENT:
2009-2014Flexibility and commitment in post-effector CD4 lymphocytes
NIH 1 R01 AI077528-02 (modular annual direct costs $250,000)
2010-2014Impact of IKKB and AurK Inhibitors on Host Immunity and Melanoma
NIH 1 R01 CA116021-08 (PI - Richmond, Ann W.)
2011-2014Roles of rictor in mTOR signaling, differentiation & immune memory
via Akt and PKC
NIH 1 R01 HL106812-01
(modular annual direct costs $250,000; 1/15/2011 – 11/30/2014 <4 yr>)
2011-2016Epithelial IL4Ralpha Regulates Colon Tumor Progression
NIH 1 R01 CA157781-02 (PI - Fingleton, Barbara F.)
pending:
2012-2014NIH / NCI R21 application, “Provocative Questions in Cancer”
(dual PI application with J. Chen, M.D., Ph.D.
in planning or preparation:(timing & titles are tentative)
2013-2018Regulation of recall antibody responses by IL-4, STAT6,
& their affiliated mARTNIH 1 R01
2013-2018Regulation of B lineage fate choices and antibody production by mTOR.
BIBLIOGRAPHY:
Original reports:
1. Stahl PD, Boothby M, Owens JW, Gammon K. 1974. Studies with rat liver microsomal ß- glucuronidase. Methodological Devel. Biochem. 14: 271-279.
2. Boothby M, Daniels-McQueen S, McWilliams D, Zernik M, Boime I. 1980. Human chorionic gonadotropin alpha and beta subunit mRNAs: Translatable levels during pregnancy and molecular cloning of sequences complementary to hCG. In: Segal S., ed. Chorionic Gonadotropin. New York: Plenum Press, 253-275
(original report of hCG and hCG cDNA cloning; appeared in symposium volume).
3. Boothby M, Ruddon RW, Anderson C, McWilliams D, Boime I. 1981. A single gonadotropin alpha subunit gene in normal tissue and tumor-derived cell lines. J Biol Chem. 256: 2151-2157.
4. Hoshina M, Boothby M, Boime I. 1982. Cytological localization of choriogonadotropin alpha and placental lactogen mRNAs during development of the human placenta. J Cell Biol. 93: 190-198.
5. Boothby M, Kukowska J, Boime I. 1983. Polysomal synthesis of human chorionic gonadotropin alpha and beta subunits is imbalanced and reflects imbalanced mRNA levels. J Biol Chem. 258: 9250-9253.
6. Policastro P, Ovitt C, Hoshina M, Fukuoka H, Boothby M, Boime I. 1983. The beta subunit of human chorionic gonadotropin is encoded by multiple genes. J Biol Chem. 258:11492-11499.
7. Hoshina M, Boothby M, Hussa R, Pattillo R, Camel M, Boime I. 1984. Segregation patterns of polymorphic restriction sites of the gene encoding the alpha subunit of human chorionic gonadotropin in trophoblastic disease. Proc Nat'l Acad Sci USA. 81: 2504-2507.
8. Liou H-C, Boothby M, Glimcher LH. 1988. Distinct cloned class II MHC DNA-binding proteins recognize the X box transcription element. Science 242: 69-71.
9. Boothby M, Gravallese E, Liou H-C, Glimcher LH. 1988. A DNA-binding protein regulated by IL-4 and by differentiation in B cells. Science 242: 1559-1562.
10. Boothby, M., Liou H-C, Glimcher LH. 1989. Differences in DNA sequence specificity among MHC Class II X box binding proteins. J. Immunol. 142: 1005-1014. continued
11. Gravallese E, Boothby M, Smas C, Glimcher LH. 1989. A lipopolysaccharide-induced DNA binding protein in B cells is distinct from NF-B. Mol. Cell Biol. 9: 3184-3192.
12. Liou HC, Boothby M, Finn PW, Davidon R, Nabavi N, Zeleznik-Le NJ, Ting JP-Y, Glimcher LH. 1990. A new member of the leucine zipper class of proteins which binds to the HLA DRA promoter. Science 247: 1581-1584.
13. Finn PW, Kara CJ, Van TT, Douhan J III, Boothby M, Glimcher LH. 1990. The presence of a DNA-binding complex correlates with E class II gene expression. EMBO Journal 9: 1543-1549.
Faculty era papers
14. Whitley MZ, Sisk R, Ivashkiv L, Finn PW, Glimcher LH, Boothby M. 1991. Non-consensus DNA sequences function in a cell-type specific enhancer of the class II MHC gene A. International Immunology 3: 877-888.
15. Gravallese E, Darling J, Glimcher LH, Boothby M. 1991. Relationship of LPS and IL-4 in control of transcription of the murine class II MHC A gene. J. Immunol. 147: 2377-2383.
16. Rothman P, Li S, Gorham B, Glimcher LH, Alt F, Boothby M. 1991. Identification of a Conserved IL-4 /LPS Responsive Element Located at the Promoter of Germline Transcripts. Mol. Cell Biol. 11: 5551-5561.
17. Casey LS, Lichtman AH, Boothby M. 1992. IL-4 induces IL-2 receptor p75 chain gene gene expression, and IL-2 dependent proliferation in mouse T lymphocytes. J. Immunol. 148: 3418-3426.
18. Whitley MZ, Cheng H-W, Tomasi TB, Boothby M. 1993. Distinct IL-4 response mechanisms of the MHC gene A in different mouse B cell lines. Molec. Immunol. 30: 821-832.
19. Kim J, Reeves R, Rothman P, Boothby M. 1995. The non-histone chromosomal protein HMG-I(Y) contributes to repression of the immunoglobulin heavy chain germline epsilon promoter. Eur. J. Immunol. 25, 788-798.
20. Wang D-Z, Ray P, and Boothby M. 1995. Rapamycin inhibits interleukin 4-inducible phosphorylation of HMG-I(Y). J. Biol. Chem. 270, 22924-22932.
21. Wang D-Z, Cherrington AL, Famakin-Mosuro BM, and Boothby M. 1996. Independent pathways to de-repression of the mouse immunoglobulin heavy chain epsilon germ-line promoter. Int'l Immunol. 8: 977-989.
22. Kovalik J-P, Ansari B, and Boothby M. 1996. Rapid commitment to negative selection of a thymocyte line independent of CD4 co-engagement. J. Immunol. 157: 5290-5299.
23. BoothbyM., Mora AL, Scherer DC, Brockman J, and Ballard DW. 1997. Perturbation of the T lymphocyte lineage in transgenic mice expressing a constitutive repressor of NF-B. J. Exp. Med. 185: 1897-1907.
24. Wang DZ, Zamorano J, Keegan A, and Boothby M. 1997. HMG-I(Y) phosphorylation status as a nuclear target regulated through the I4R motif of the IL-4 receptor. J. Biol. Chem. 272: 25083-25090.
25. Lee SY, Kaufman DR, Mora AL, Santana A, Boothby M, and Choi Y. 1998. Stimulus-dependent synergism of the anti-apoptotic TRAF2 and NF-B pathways. J. Exp. Med. 188: 1381-1384.
26. Zhang F, Wang DZ, Boothby M, Penix LA, and Flavell RA, Aune TM. 1998. Regulation of the activity of IFN- promoter elements during T helper cell differentiation. J. Immunol. 161: 6105-6112.
continued
27. Youn J, Chen J, Goenka S, Aronica MA, Mora AL, Correa V, Sheller JR, and Boothby M. 1998. In vivo function of an IL-2R / IL-4R cytokine receptor chimera potentiates allergic airway disease. J. Exp. Med. 188: 1803-1816.
28. Aune TM, Mora AL, Kim S, Boothby M*, and Lichtman AH. 1999. Costimulation reverses the defect in IL-2 but not effector cytokine production by T cells with impaired IB degradation. J. Immunol. 162:5805-5812. (* corresponding author)
29. Seetharaman R, Mora A, Nabozny G, Boothby M, and Chen J. 1999. Essential role of T cell NF-B activation in collagen-induced arthritis. J. Immunol. 163: 1577-1583.
30. Mora AL, Chen D., Boothby M, Rubin D. 1999. Lineage-specific differences among CD8+ T cells in their dependence on NF-B/Rel signaling. Eur. J. Immunol. 29: 2968-2980.
31. Goenka S, Youn J, Dzurek L, Schindler U, Yu-Lee L-y, Boothby M. 1999. Paired Stat6 C-terminal transcription activation domains required both for inhibition of an interferon-responsive promoter and for trans -activation. J. Immunol. 163: 4663-4672.
32. Aronica MA, Mora AL, Mitchell DB, Johnson JE, Finn PW, Sheller J, and Boothby M. 1999. Preferential role for NF-B / Rel signaling in the type 1 but not type 2 T cell-dependent immune response in vivo. J. Immunol. 163: 5116-5124.
33. Powell WC, Fingleton B., Wilson CL, Boothby M, and Matrisian LM. 1999. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and
potentiates epithelial cell apoptosis. Current Biol. 9:1441-1447.
34. Aronica MA, Goenka S, Boothby M. 2000. IL-4-dependent induction of Bcl-2 & Bcl-X in T lymphocytes through a Stat6- & PI 3-kinase-independent pathway. Cytokine. 6: 578-87.
35. Mora AL, Youn J, Keegan AD, and Boothby M. 2001. Mechanisms of NF-B/Rel participation in the lymphokine-dependent proliferation of T lymphoid cells. J. Immunol. 166: 2218-2227.
36. Chen Y, Rosloniec E, Boothby M, and Chen J. 2001. Redirection of T cell effector function in vivo and enhanced collagen-induced arthritis mediated by an IL-2R / IL-4R chimeric cytokine receptor transgene. J. Immunol. 166, 4163-4169.
37. Zamorano J, Mora AL, Boothby M, and Keegan AD. 2001. NF-kappaB activation plays an important role in the IL-4-induced protection from apoptosis. Int. Immunol. 13: 1479-1487.
38. Mora, AL, Stanley SA, Armistead W, Chan AC, and Boothby M. 2001. Inefficient ZAP-70 phosphorylation and decreased thymic selection in vivo result from inhibition of NF-B/Rel. J. Immunol. 167: 5628-5635.
39. Finn PW, Stone JR, Boothby MR, Perkins DL. 2001. Inhibition of NF-kappaB-dependent T cell activation abrogates acute allograft rejection. J. Immunol. 167: 5994-6001.
40. Chen Y, Rosloniec E, Price J, Boothby M, and Chen J. 2002. Constitutive expression of Bcl-xL in the T Lineage Attenuates Collagen-Induced Arthritis in Bcl-xL transgenic mice. Arthritis Rheum. 46: 514-521.
41. Haley KJ, Ciota A, Contreras JP, Boothby MR, Perkins DL, and Finn PW. 2002. Alterations in lung collectins in an adaptive allergic immune response. Am. J. Physiol. Lung Cell. Mol. Physiol. 282:L573-84.
42. Harlin H., Hwang KW, Kim O, Thompson CB, Boothby M, and Alegre M-L. 2002. CTLA-4
engagement regulates NF-B activation in vivo. Eur. J. Immunol. 32:2095-2104.